Portman Square Capital’s Johnson & Johnson JNJ Stock Holding History

Portman Square Capital’s Portfolio JNJ Stock Details JNJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-202,000	Closed	-$33.5M	–	211
2025 Q1	$33.5M	Buy	+202,000	New	+$31.6M	0.89%	30
2023 Q2	–	Sell	-13,200	Closed	-$2.05M	–	430
2023 Q1	$2.05M	Hold	13,200	–	–	0.09%	160
2022 Q4	$2.33M	Buy	+13,200	New	+$2.28M	0.17%	111

Other funds holding JNJ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Portman Square Capital's JNJ Position: Q2 2023 in Review

Portman Square Capital sold out of Johnson & Johnson (JNJ) in Q2 2023, closing a stake of 3,265 shares — an estimated $506K sold.

Portman Square Capital first reported a position in JNJ in Q4 2022 and held it in 2 quarters. The position peaked at $577K in Q4 2022. 3,752 funds tracked by Wall St. Rank hold JNJ as of Q2 2023.

Portman Square Capital reported no remaining Johnson & Johnson position as of Q2 2023 after selling out during the quarter.
Portman Square Capital sold 3,265 Johnson & Johnson shares in Q2 2023, an estimated $506K.
Portman Square Capital first reported a position in Johnson & Johnson in Q4 2022 and held it in 2 quarters.
Portman Square Capital's Johnson & Johnson position peaked at $577K in Q4 2022.
3,752 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2023.

Based on Portman Square Capital's 13F filing for Q2 2023, filed 26 Jul 2023.